Clinical Trial Update: Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the combination of selinexor and docetaxel for recurrent or metastatic squamous cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Selinexor (selinexor)

Snippet

Sponsor: Erin Bertino | Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN